Understanding Treatment Adherence Among Individuals With Rapid Cycling Bipolar Disorder
Rapid Cycling Bipolar Disorder (RCBPD), Subjective Illness Experience and Gender
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Bipolar Disorder (BPD), also known as manic-depressive illness, is a disorder that causes frequent shifts in an individual's mood, energy, and ability to function. An individual with BPD may go through periods of mania, which are characterized by increased energy, irritability, and an excessively "high" euphoric mood. The manic periods are followed by periods of depression, which are characterized by decreased energy, feelings of hopelessness, and anxiety. Rapid cycling bipolar disorder (RCBPD) is a type of BPD in which the individual experiences four or more episodes of mania and depression per year. The rapid shift between the manic and depressive episodes makes it imperative that individuals with RCBPD strictly manage their illness with medication. Many BPD medications have been developed recently; however, there are still many individuals who do not respond well to medication treatment. Research has shown that the way individuals experience illness has an effect on their response to medication. The purpose of this study is to gain insight into how individuals with RCBPD perceive and respond to medication treatment. Factors such as gender, degree of social support, drug and alcohol usage, and attitudes towards medication will be evaluated to understand how they affect medication and treatment adherence.
This study will consist of 1 visit, which will last approximately 2 and ½ hours and will include an anthropological interview and numerous standardized psychological questionnaires. The interview and questionnaires will assess participants' attitudes toward BPD treatment; psychiatric illness severity, including symptoms of mania and depression; expectations regarding recovery, stigma, and quality of life; and medication adherence.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Ohio
-
Beachwood, Ohio, Förenta staterna, 44122
- Northeast Ohio Health Services
-
Cleveland, Ohio, Förenta staterna, 44106
- University Hospitals Of Cleveland
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Clinical diagnosis of rapid cycling variant of bipolar disorder type I; diagnosed 2 to 20 years prior to study entry
- Has experienced an index depressive episode
- Received treatment with medication to stabilize mood for at least 6 months prior to study entry
- Lives in the Northeast Ohio area and is a patient at either Northeast Ohio Health Services or The Mood Disorders Clinic at University Hospitals of Cleveland
Exclusion Criteria:
- Unable/unwilling to participate in psychiatric interviews
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Qualitative Interview
Participants with rapid cycling bipolar disorder (RCBPD)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The Subjective Experience of Medication Interview (SEMI)
Tidsram: Baseline
|
The Subjective Experience of Medication Interview (SEMI) is a qualitative, semi-structured assessment of subjective experience of mental illness, which requires approximately 60-120 minutes to administer.
Illness experience domains assessed include illness attitudes, attributions and behaviors, social relations, treatment history and medication experience, self-medication, quality of life, stigma, culture/ethnicity, and health care logistics.
The SEMI has been modified for use in populations with Bipolar Disorder.
|
Baseline
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Hamilton Depression Rating Scale (HAMD)
Tidsram: Baseline
|
A rater administered rating to scale to measure symptoms of depression, and is the most commonly utilized rating scale to assess depressive symptoms in bipolar depression clinical studies.
|
Baseline
|
|
Clinical Global Impression (CGI)
Tidsram: Baseline
|
Global illness severity is measured with the Clinical Global Impressions (CGI), a widely used scale which evaluates illness severity on a 1 to 7 point continuum.
Severity of illness ratings on the CGI have reported reliability scores ranging from 0.66-0.41.
|
Baseline
|
|
Insight and Treatment Attitudes Questionnaire (ITAQ)
Tidsram: Baseline
|
An 11-item rating scale to evaluate patient recognition of illness and need for treatment in psychiatric illness.
Each ITAQ item is scored on a 0 to 2 scale (0 = no insight, 2 = good insight), and the scale has high interrater reliability (r=0.82,
p<.001) (McEvoy 1981).
Construct validity, checked by correlating scores with an open interview is also good (r=.85,
p<.001).
|
Baseline
|
|
Illness Behavior Questionnaire (IBQ)
Tidsram: Baseline
|
A 62-item instrument designed to measure a respondent's attitudes, ideas, affects and attributions in relation to illness.
The IBQ is a self-reported scale, in which the respondent answers "yes" or "no" to each question regarding illness experience and subjective response.
There are seven major subscales derived through factor analysis.
The IBQ has very good stability, with one-to-twelve week test-retest correlations ranging from .67-.85 for the subscales.
It has good face and content validity.
|
Baseline
|
|
Attitude Towards Mood Stabilizers Questionnaire (AMSQ)
Tidsram: Baseline
|
A modification of the Lithium Attitudes Questionnaire (Harvey 1991) which evaluates an individual's attitudes towards mood stabilizing medication (Adams and Scott 2000).
The AMSQ comprises 19 items grouped into 7 subscales: general opposition to prophylaxis (4 items), denial of illness severity (3 items), negative attitudes toward drugs in general (3 items), and lack of information about mood stabilizers (1 item).
Higher scores on each subscale represent more negative attitudes toward mood stabilizers.
Reliability for the 19 items ranges from 57.6 % to 96.9%.
|
Baseline
|
|
Multidimensional Health Locus of Control Scale (MHLC)
Tidsram: Baseline
|
An 18-item instrument that measures three dimensions of locus of control of reinforcement as it pertains to health (internal, IHLC: external-chance, CHLC: and external powerful others, PHLC).
Scoring is from 6-36 with higher scores indicating stronger beliefs.
The internal consistency reliability using Cronbach's alpha ranges from .67 to .77
for the three dimensions, and the measure has fairly good criterion validity (Wallston 1978).
|
Baseline
|
|
Treatment Adherence
Tidsram: Baseline
|
Treatment adherence will be evaluated in the following three ways: 1) The primary measure will be the Tablet Routines Questionnaire (TRQ, Peet 1991) which is a validated assessment of adherence among individuals with bipolar disorders (Scott 2002, Peet 1991), 2) Blood level of mood stabilizing and antipsychotic medications will be identified from the patient record.
This has been identified as a standard of care in numerous guidelines for the treatment of bipolar disorder (American Psychiatric Association 2000, Goldberg 2000).
3) Adherence with clinic visits for the previous three month time period will be calculated as a percentage.
|
Baseline
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Publikationer och användbara länkar
Allmänna publikationer
- Sajatovic M, Jenkins JH, Cassidy KA, Muzina DJ. Medication treatment perceptions, concerns and expectations among depressed individuals with Type I Bipolar Disorder. J Affect Disord. 2009 Jun;115(3):360-6. doi: 10.1016/j.jad.2008.10.002. Epub 2008 Nov 8.
- Sajatovic M, Jenkins JH, Safavi R, West JA, Cassidy KA, Meyer WJ, Calabrese JR. Personal and societal construction of illness among individuals with rapid-cycling bipolar disorder: a life-trajectory perspective. Am J Geriatr Psychiatry. 2008 Sep;16(9):718-26. doi: 10.1097/JGP.0b013e3180488346. Epub 2007 Dec 10.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- K23MH065599-02 (U.S.S. NIH-anslag/kontrakt)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .